BOLD (Boundless Bio) Non Operating Income : $-0.02 Mil (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Non Operating Income?

Non Operating Income is income or expense that comes from miscellaneous sources. Boundless Bio's Non Operating Income for the three months ended in Mar. 2025 was $-0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.02 Mil.

Boundless Bio Non Operating Income Historical Data

The historical data trend for Boundless Bio's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Non Operating Income Chart

Boundless Bio Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Non Operating Income

-0.01

-0.10

0.08

0.01

Boundless Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Non Operating Income	Get a 7-Day Free Trial							0.03	0.03	0.03	-0.09	-

Boundless Bio Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.02 Mil.

Boundless Bio Non Operating Income Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Non Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

10955 Alexandria Way, Suite 100, San Diego, CA, USA, 92121

Website

https://www.boundlessbio.com

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.